alejandro.sanabria@americaneagle.com, Author at CureDuchenne

Ryan Getzlaf and Other Anaheim Ducks Teammates to Play in the 4th Annual Getzalf Golf Shootout to Benefit CureDuchenne on September 7

September 3, 2014

Ryan Getzlaf, captain of the Anaheim Ducks, is hosting the fourth annual Getzlaf Golf Shootout to benefit CureDuchenne, a nonprofit that raises awareness and funds research to find a cure for Duchenne muscular dystrophy. This two-day charity golf event includes a reception at Sutra Lounge in Costa Mesa on September 6 and a golf tournament held at the Monarch Beach Golf Links in Dana Point on September 7. Each foursome will be teamed up with a professional athlete or celebrity for an exciting day on the green

Swimming for Duchenne

August 20, 2014

CureDuchenne and the Duchenne Therapy Network are pleased to provide a video and educational information on the swimming activities for those with Duchenne muscular dystrophy. The pool is great […]

Prosensa is working towards long-term access to drisapersen

August 15, 2014

CureDuchenne is pleased to share the latest update to patient groups from Prosensa, which outlines their progress to date, as well as future plans. CureDuchenne announced earlier in the week our […]

Prosensa is working towards long-term access to drisapersen

August 15, 2014

As previously communicated, Prosensa received guidance from the United States Food and Drug Administration (FDA) on June 2, in which a regulatory pathway for accelerated approval was outlined for drisapersen.

CureDuchenne Extends Prosensa Pipeline Collaboration With $7 Million

August 13, 2014

Comment Now Follow Comments

CureDuchenne, a California-based non-profit organization dedicated to finding a cure for Duchenne Muscular Dystrophy (DMD), announced on Tuesday their $7 million (â‚¬5 million) collaboration with the biotechnology company, Prosensa Holding N.V.

Accelerating Access to Duchenne Drug Candidates

August 12, 2014

Yesterday Prosensa and CureDuchenne announced an extension of our collaboration and a path to provide access to four experimental drugs for Duchenne patients. Ten years ago, CureDuchenne provided funding to […]

Dr. Flanigan’s Duplication 2 Duchenne Mutation – Nature Medicine

August 11, 2014

We are very excited to see that Dr. Kevin Flanigan’s work on a rare Duchenne mutation, a duplication on exon 2, was published in Nature Medicine. This prestigious magazine reported […]

CureDuchenne Announces $7 Million (Ì¢Û_åÂ5M) Collaboration with Prosensa to Help Speed Access to Treatments for Duchenne Muscular Dystrophy Patients

August 11, 2014

CureDuchenne announced today a new $7 million (Ì¢Û_åÂ5M) collaboration with the biotechnology company Prosensa (NASDAQ: RNA) to help get experimental medicines to patients with Duchenne Muscular Dystrophy more quickly.

Translation from a DMD exon 5 IRES results in a functional dystrophin isoform that attenuates dystrophinopathy in humans and mice

August 10, 2014

Most mutations that truncate the reading frame of the DMD gene cause loss of dystrophin expression and lead to Duchenne muscular dystrophy